148 related articles for article (PubMed ID: 17919428)
21. In vivo quantification of the structural abnormalities in psoriatic microvessels before and after pulsed dye laser treatment.
Hern S; Stanton AW; Mellor RH; Harland CC; Levick JR; Mortimer PS
Br J Dermatol; 2005 Mar; 152(3):505-11. PubMed ID: 15787819
[TBL] [Abstract][Full Text] [Related]
22. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.
Feldman SR; Kimball AB; Krueger GG; Woolley JM; Lalla D; Jahreis A
J Am Acad Dermatol; 2005 Nov; 53(5):887-9. PubMed ID: 16243150
[TBL] [Abstract][Full Text] [Related]
23. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.
Gottlieb AB; Chamian F; Masud S; Cardinale I; Abello MV; Lowes MA; Chen F; Magliocco M; Krueger JG
J Immunol; 2005 Aug; 175(4):2721-9. PubMed ID: 16081850
[TBL] [Abstract][Full Text] [Related]
24. Selective persistence of dermal CD8+ T cells in lesional plaque psoriasis after clobetasol-17 propionate treatment.
Bovenschen HJ; Vissers WH; Seyger MM; van de Kerkhof PC
Acta Derm Venereol; 2005; 85(2):113-7. PubMed ID: 15823902
[TBL] [Abstract][Full Text] [Related]
25. [Soluble tumor-necrosis-factor-alpha receptor type-1 as a marker of activity of psoriasis vulgaris and effects of its treatment].
Serwin AB; Sokołowska M; Chodynicka B
Przegl Lek; 2005; 62(2):95-7. PubMed ID: 16095152
[TBL] [Abstract][Full Text] [Related]
26. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis.
Goedkoop AY; de Rie MA; Picavet DI; Kraan MC; Dinant HJ; van Kuijk AW; Tak PP; Bos JD; Teunissen MB
Arch Dermatol Res; 2004 Apr; 295(11):465-73. PubMed ID: 14968366
[TBL] [Abstract][Full Text] [Related]
27. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4.
Bachelez H; Flageul B; Dubertret L; Fraitag S; Grossman R; Brousse N; Poisson D; Knowles RW; Wacholtz MC; Haverty TP; Chatenoud L; Bach JF
J Autoimmun; 1998 Feb; 11(1):53-62. PubMed ID: 9480723
[TBL] [Abstract][Full Text] [Related]
28. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study.
Strober BE; Siu K; Alexis AF; Kim G; Washenik K; Sinha A; Shupack JL
J Am Acad Dermatol; 2005 Jun; 52(6):1082-4. PubMed ID: 15928633
[TBL] [Abstract][Full Text] [Related]
29. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
Jacobson CC; Kimball AB
Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
[TBL] [Abstract][Full Text] [Related]
30. The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of hallopeau.
Kazinski K; Joyce KM; Hodson D
J Drugs Dermatol; 2005; 4(3):360-4. PubMed ID: 15898294
[TBL] [Abstract][Full Text] [Related]
31. Soluble tumor necrosis factor alpha receptor type 1 in psoriasis patients treated with narrowband ultraviolet B.
Serwin AB; Sokolowska M; Chodynicka B
Photodermatol Photoimmunol Photomed; 2005 Aug; 21(4):210-1. PubMed ID: 15998370
[TBL] [Abstract][Full Text] [Related]
32. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept.
Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
Ann Rheum Dis; 2003 Jun; 62(6):561-4. PubMed ID: 12759295
[TBL] [Abstract][Full Text] [Related]
33. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis.
Ortonne JP; Lebwohl M; Em Griffiths C;
Eur J Dermatol; 2003; 13(2):117-23. PubMed ID: 12695125
[TBL] [Abstract][Full Text] [Related]
34. Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions.
Horroccks A; Ormerod AD; Duncan JI; Thomson AW
Clin Exp Immunol; 1989 Nov; 78(2):166-71. PubMed ID: 12412743
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons.
Barrier BF; Bates GW; Leland MM; Leach DA; Robinson RD; Propst AM
Fertil Steril; 2004 Mar; 81 Suppl 1():775-9. PubMed ID: 15019808
[TBL] [Abstract][Full Text] [Related]
36. [Refractory psoriasis treatment with etanercept].
Mahiques Santos L; Martínez-Menchón T; Sánchez Carazo JL; Pérez-Ferriols A; Soriano Navarro CJ; Fortea Baixauli JM
Med Clin (Barc); 2005 Sep; 125(10):371-3. PubMed ID: 16185546
[TBL] [Abstract][Full Text] [Related]
37. Cell-mediated immune response in psoriasis and psoriatic arthritis.
Ventura M; Colizzi M; Ottolenghi A; Polignano A; Sinisi DA; Rantuccio F; Antonaci S; Bonomo L
Recenti Prog Med; 1989 Sep; 80(9):449-54. PubMed ID: 2687984
[TBL] [Abstract][Full Text] [Related]
38. The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: it's time to get serious.
Wallace DJ
J Rheumatol; 2003 Sep; 30(9):1897-9. PubMed ID: 12966586
[No Abstract] [Full Text] [Related]
39. Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT).
Gonzalez-Vicent M; Diaz MA; Sevilla J; Madero L
Ann Hematol; 2003 Oct; 82(10):649-53. PubMed ID: 12928753
[TBL] [Abstract][Full Text] [Related]
40. Blood flow in psoriatic plaques before and after selective treatment of the superficial capillaries.
Hern S; Stanton AW; Mellor RH; Harland CC; Levick JR; Mortimer PS
Br J Dermatol; 2005 Jan; 152(1):60-5. PubMed ID: 15656801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
